Effect of biosimilar market entry on cost of biologics in the United States: The case of filgrastim

被引：0
|
作者：
Mouslim, Morgane [1 ]
Alexander, Caleb [1 ]
Segal, Jodi [1 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4575
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [1] Effect of biosimilar market entry on utilization of biologics in the united states: the case of filgrastim
    Mouslim, Morgane
    Segal, Jodi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 646 - 647
  • [2] Biosimilar use in the United States: An analysis of filgrastim and infliximab
    Dutcher, Sarah K.
    Eworuke, Efe
    Fazio-Eynullayeva, Elnara
    Dee, Elizabeth
    Nguyen, Michael D.
    Panozzo, Catherine A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 475 - 475
  • [3] Trends in the utilization of short-acting filgrastim following the United States market launch of the first biosimilar
    Jazowski, Shelley
    Dusetzina, Stacie
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 482 - 482
  • [4] Filgrastim-sndz debuts as the frst biosimilar approved in United States
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (12): : 420 - 422
  • [5] INFLIXIMAB MARKET SHARE AND ASSOCIATED COST SAVINGS FOLLOWING BIOSIMILAR MARKET ENTRY
    Paglinco, Samantha
    Abdel-Rasoul, Mahmoud
    Mcnicol, Megan
    Boyle, Brendan
    Dotson, Jennifer
    Michel, Hilary
    Maltz, Ross
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S51 - S51
  • [6] The effect of generic market entry on antibiotic prescriptions in the United States
    Kallberg, Cecilia
    Hudson, Jemma
    Salvesen Blix, Hege
    Ardal, Christine
    Klein, Eili
    Lindbaek, Morten
    Outterson, Kevin
    Rottingen, John-Arne
    Laxminarayan, Ramanan
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [7] The effect of generic market entry on antibiotic prescriptions in the United States
    Cecilia Kållberg
    Jemma Hudson
    Hege Salvesen Blix
    Christine Årdal
    Eili Klein
    Morten Lindbæk
    Kevin Outterson
    John-Arne Røttingen
    Ramanan Laxminarayan
    Nature Communications, 12
  • [8] Implementation of a Market Entry Reward within the United States
    Daniel, Gregory W.
    Schneider, Monika
    Lopez, Marianne Hamilton
    McClellan, Mark B.
    JOURNAL OF LAW MEDICINE & ETHICS, 2018, 46 : 50 - 58
  • [9] Effect of biosimilar basaglar entry in the long-acting insulin market
    Rashidi, Emaan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 407 - 407
  • [10] Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim
    Grewal, Simrun
    Ramsey, Scott
    Balu, Sanjeev
    Carlson, Josh J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (04) : 447 - 454
12345